Tag: Major Depressive Disorder

Executive Summary For decades, neuropsychiatry was a field characterized by high failure rates and incremental progress, making it a challenging ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to ...

- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ ...

In a recent interview on NewsNation's On Balance, FDA Commissioner Dr. Marty Makary affirmed that advancing psychedelic therapies is now ...

In the fast-evolving landscape of biotechnology, one company is making waves in the mental health treatment space with its innovative ...